Credit Suisse analyst Vamil Divan maintained a Hold rating on Bristol Myers (NYSE: BMY) on October 12 and set a price target of $61. The company’s shares closed on Friday at $57.51.
According to TipRanks.com, Divan is a 1-star analyst with an average return of -1.6% and a 45.6% success rate. Divan covers the Healthcare sector, focusing on stocks such as Aimmune Therapeutics, Johnson & Johnson, and Merck & Company.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Bristol Myers with a $61.50 average price target, a 6.9% upside from current levels. In a report issued on October 8, Guggenheim also initiated coverage with a Hold rating on the stock with a $70 price target.
.
See today’s analyst top recommended stocks >>
Bristol Myers’ market cap is currently $93.85B and has a P/E ratio of 250.04. The company has a Price to Book ratio of 7.62.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Bristol-Myers Squibb Co. engages in the discovery, development, licensing, manufacture, marketing, distribution, and sale of biopharmaceutical products. It includes chemically-synthesized drugs or small molecules and products produced from biological processes called biologics. The company was founded in August 1933 and is headquartered in New York, NY.
